Compare ED & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ED | NTRA |
|---|---|---|
| Founded | 1884 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3B | 39.1B |
| IPO Year | 2009 | 2015 |
| Metric | ED | NTRA |
|---|---|---|
| Price | $108.80 | $309.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | $107.00 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ 7.63 | 0.65 |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $16,918,000,000.00 | $210,939,000.00 |
| Revenue This Year | $9.18 | $18.08 |
| Revenue Next Year | $4.49 | $19.65 |
| P/E Ratio | $42.67 | ★ N/A |
| Revenue Growth | ★ 10.89 | N/A |
| 52 Week Low | $94.96 | $156.71 |
| 52 Week High | $116.23 | $326.03 |
| Indicator | ED | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 65.13 |
| Support Level | $104.38 | $186.96 |
| Resistance Level | $109.33 | N/A |
| Average True Range (ATR) | 2.10 | 11.49 |
| MACD | -0.18 | 3.54 |
| Stochastic Oscillator | 36.69 | 78.64 |
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York, including New York City, and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.